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Introduction
Chronic migraine is a common and debilitating head-
ache syndrome.
Botulinum neurotoxin A(BoNT A), produced by the
anaerobic bacterium clostridium botulinum has been
recently employed for patients suffering from chronic
migraine.
Aims
BoNT A has been used in our clinical experience for
treating patients referring to our headache centre and
suffering from chronic migraine with medication overuse.
Method
Forty four patients, suffering from chronic migraine with
medication overuse, mean age 51.1 + 7.9, have been
submitted to a withdrawal from medications in a day
hospital setting, successively they have been treated by
BoNT A injection in multiple sites according to the pro-
tocol of the PREEMPT study at the dosage of 155 U for
31 sites. Every session of local injection was repeated
every three months for a period of one year.
Results
Twenty three patients achieved the 6 months follow up.
The results, recorded by the diary, evidenced a signifi-
cant decrease in days of headache/month (pre 20.4 ± 6.9
post 13.7 ± 9.1 p<0.005) and in medication intake/
month (pre 22.2 ± 6.9 post 13.8 ± 9.2 p < 0.0005).
Conclusion
Although these results are preliminary they led to
intense efforts to evaluate analgesic properties of BoNT
A and to assess their clinical applicability.
The pharmacological profile of BoNT A makes it a
good candidate for migraine prevention as proposed in
the PREEMPT study. Its long duration of action
(3 months) makes it particularly attractive for patients
who are not compliant with the daily use of preventive
medications, or if they cannot tolerate them or when
they are refractory to preventive medications.
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